Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 6 min read

What is DSIP?

DSIP (delta sleep-inducing peptide) is a research peptide studied in animal models of sleep regulation and neurotransmitter balance. This page covers its identifiers, the mechanisms under investigation, and the limits of

peptides-pro Editorial

Delta sleep-inducing peptide (DSIP) is a short peptide that has been investigated in laboratory research for its effects on sleep regulation and neurotransmitter balance. The compound is also referred to in the literature as delta sleep-inducing peptide and by the abbreviation DSIP. The evidence block provided for this page does not specify the amino acid sequence, molecular formula, or molecular weight of DSIP, so those identifiers are not reported here. DSIP is studied as a peptide agent, and the research summarised below centres on its interactions with neurotransmitter systems and its distribution across the blood-brain barrier in animal models.

The work described in the evidence centres on DSIP fusion peptides and their capacity to cross the blood-brain barrier, with downstream effects on neurotransmitter levels in a mouse model of insomnia [1].

Research Studies

DSIP and neurotransmitter balance in a PCPA-induced insomnia mouse model

A study using p-chlorophenylalanine (PCPA)-induced insomnia in mice investigated the sleep-promoting mechanism of a DSIP fusion peptide construct, DSIP-CBBBP, which combines DSIP with a blood-brain barrier-crossing peptide [1]. The research aimed to clarify how the fusion peptide affects neurotransmitter levels and sleep regulation, and to analyse its composition and structure [1]. PCPA is used to deplete serotonin, and the model is described as akin to traditional methods for evaluating sleep-promoting activity in fusion peptides [1]. The findings reported in that study relate to mice; no human data are presented in the evidence block.

DSIP and blood-brain barrier crossing in the DSIP-CBBBP fusion design

The DSIP-CBBBP construct was designed to combine DSIP with a peptide sequence that facilitates crossing of the blood-brain barrier [1]. The study investigated the properties of Pichia pastoris-secreted DSIP-CBBBP fusion peptides, including their potential sleep-enhancing and neurotransmitter-balancing effects [1]. The evidence block does not provide quantitative permeability values or a direct comparison between DSIP alone and the fusion peptide, so no such comparison is made here. The work is described as an investigation in mice [1].

DSIP and Pichia pastoris secretion for peptide production

The DSIP-CBBBP fusion peptides studied in the insomnia model were secreted from Pichia pastoris [1]. This expression system is noted in the evidence as the source of the fusion peptides whose composition and structure were analysed [1]. The evidence block does not report yield, purity, or structural data, so those details are not included here. The relevance of this work to DSIP research is that it describes a production route for a DSIP-containing fusion peptide prior to its evaluation in an animal model [1].

DSIP and peptide synthesis methods: N-to-C elongation

A separate line of methodological work concerns peptide synthesis. Traditional peptide synthesis using chain elongation from C- to N-terminus is described as reliable but generates large quantities of chemical waste derived from protecting groups and condensation reagents [2]. An alternative N-to-C elongation strategy has been reported that uses catalytic peptide thioacid formation and oxidative peptide bond formation with main chain-unprotected amino acids under aerobic conditions [2]. That method is described as applicable to both iterative peptide couplings and convergent approaches [2]. This work is about peptide synthesis methodology generally and is not a study of DSIP itself; it is included here because it bears on how peptides such as DSIP can be assembled in the laboratory [2].

DSIP and Raman deuterium stable isotope probing in Escherichia coli

The abbreviation DSIP is also used in the microbiology literature for deuterium stable isotope probing, a technique applied in Escherichia coli to sense bactericidal and bacteriostatic modes of antimicrobial action [3][4]. In that context, DSIP refers to the analytical method, not to delta sleep-inducing peptide. The mode of action of antibiotics can be broadly classified as bacteriostatic, which leads to arrested growth of cells, or bactericidal, which causes cell death [3][4]. The work reports the applicability of deuterium stable isotope probing in combination with Raman spectroscopy for this purpose [3][4]. This is a distinct use of the acronym and should not be conflated with research on delta sleep-inducing peptide.

DSIP and federated data architectures: a note on acronym overlap

A further unrelated use of the DSIP acronym appears in the data-infrastructure literature, where it denotes a federated policy-governed architecture for sovereign European data spaces [5]. That work concerns trusted, sovereign, and interoperable data sharing across organisational boundaries, and discusses existing reference frameworks such as GAIA-X and the International Data Spaces Reference Architecture Model [5]. It has no relationship to delta sleep-inducing peptide and is noted here only to disambiguate the acronym.

DSIP and domain-specific information preservation in Alzheimer's disease imaging

Another unrelated use of the DSIP abbreviation appears in work on domain-specific information preservation for Alzheimer's disease diagnosis with incomplete multi-modality neuroimages [6]. That research addresses the problem of missing modality data in clinical practice and the use of imputation so that all available subjects can be used to train robust multi-modality models [6]. As with the entries above, this is an acronym collision rather than a study of delta sleep-inducing peptide.

DSIP and the scope of the available evidence

Across the evidence block, the only studies directly concerning delta sleep-inducing peptide are the investigation of DSIP-CBBBP fusion peptides in a PCPA-induced insomnia mouse model [1] and, indirectly, the peptide synthesis methodology that could be applied to its production [2]. The sleep-related findings are animal-only; the evidence block contains no human trials, no clinical endpoints, and no in vitro mechanistic data specific to DSIP. The remaining entries [3][4][5][6] use the same acronym for unrelated methods or systems and are included solely to prevent misattribution.

Acronym use Expansion Context in the evidence Source
DSIP Delta sleep-inducing peptide Sleep regulation and neurotransmitter balance; PCPA-induced insomnia mouse model [1]
DSIP Deuterium stable isotope probing Raman-based sensing of antimicrobial mode of action in Escherichia coli [3][4]
DSIP Federated policy-governed architecture Sovereign European data spaces [5]
DSIP Domain-specific information preservation Alzheimer's disease diagnosis with incomplete multi-modality neuroimages [6]

DSIP and the limits of what the evidence supports

The evidence block does not provide a sequence, formula, or molecular weight for delta sleep-inducing peptide, and it does not report receptor binding affinities, pharmacokinetic parameters, or dose-response relationships. Claims about those properties are therefore not made on this page. The sleep-related work is confined to a mouse model of PCPA-induced insomnia [1], and the synthesis methodology is general rather than DSIP-specific [2]. Any statement about effects in humans would go beyond what the evidence supports and is omitted.

If you are reading this for personal health reasons

This material is sold for laboratory research only. We do not provide dosing or medical guidance, and nothing on this page should be taken as a recommendation for personal use. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

WhatsApp